|
gptkbp:instanceOf
|
cardiac glycoside
|
|
gptkbp:approvedBy
|
1954 (US)
|
|
gptkbp:ATCCode
|
C01AA05
|
|
gptkbp:bioavailability
|
60-80%
|
|
gptkbp:brand
|
gptkb:Lanoxin
|
|
gptkbp:CASNumber
|
20830-75-5
|
|
gptkbp:contraindication
|
gptkb:ventricular_fibrillation
|
|
gptkbp:derivedFrom
|
gptkb:Digitalis_lanata
|
|
gptkbp:discoveredBy
|
gptkb:William_Withering
|
|
gptkbp:effect
|
increases cardiac contractility
slows heart rate
|
|
gptkbp:eliminationHalfLife
|
36-48 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C41H64O14
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
digoxin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits Na+/K+ ATPase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
25%
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:arrhythmia
nausea
vomiting
visual disturbances
|
|
gptkbp:synonym
|
digitalis glycoside
|
|
gptkbp:usedFor
|
gptkb:atrial_fibrillation
heart failure
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Erythromycin
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|